Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
NCT ID: NCT00183625
Last Updated: 2015-06-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
107 participants
INTERVENTIONAL
2000-06-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enhancing the Outcome of Skills Training for People With Schizophrenia
NCT00069433
Functional Rehabilitation of Older Patients With Schizophrenia
NCT00237796
Cognitive Training and Enhanced Supported Employment in Schizophrenia
NCT00339170
Reducing the Weight of Overweight Schizophrenia Patients
NCT00158366
Motivational Interviewing to Improve Work Outcomes in Schizophrenia
NCT00261716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At study entry, participants will undergo a clinical and diagnostic evaluation to determine the severity of their schizophrenia. Participants will be tapered off their regular medication for schizophrenia over 4 weeks. At the end of Week 4, they will be randomly assigned to receive either risperidone or olanzapine. Participants will then be assigned an Individual Placement and Support (IPS) specialist to assist them in finding a job. After participants secure a job, they will be randomly assigned to receive IPS either alone or with the Workplace Fundamentals Skills Training Module for 2 years. Participants' risperidone or olanzapine treatment will continue during this 2-year period. Participants will have clinic visits at study entry and Months 7, 12, and 24. At each visit, participants will complete questionnaires and will be interviewed about their schizophrenia symptoms and occupational functioning.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risperidone Plus Supported Employment
Individual Placement and Support (Supported Employment)
Risperidone
Olanzapine Plus Supported Employment
Individual Placement and Support (Supported Employment)
Olanzapine
Risperidone+Supported Employment+Skills
Individual Placement and Support (Supported Employment)
Social Skills Training
Risperidone
Olanzapine+Supported Employment+Skills
Individual Placement and Support (Supported Employment)
Social Skills Training
Olanzapine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Individual Placement and Support (Supported Employment)
Social Skills Training
Olanzapine
Risperidone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Candidate for maintenance schizophrenia treatment
* Willing to initiate and continue risperidone or olanzapine therapy for the duration of the study
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
US Department of Veterans Affairs
FED
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Semel Institute, University of California, Los Angeles
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen R. Marder, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Los Angeles Veterans Healthcare Center
Los Angeles, California, United States
Greater Manchester Mental Health Center
Manchester, New Hampshire, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.